雷利巴坦对假单胞菌来源头孢菌素酶 3（PDC-3）的抑制作用。
Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam.
机构信息
Research Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA.
Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
出版信息
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02406-17. Print 2018 May.
Abstract
is a prevalent and life-threatening Gram-negative pathogen. -derived cephlosporinase (PDC) is the major inducible cephalosporinase in In this investigation, we show that relebactam, a diazabicyclooctane β-lactamase inhibitor, potently inactivates PDC-3, with a / of 41,400 M s and a of 0.00095 s Relebactam restored susceptibility to imipenem in 62% of multidrug-resistant clinical isolates, while only 21% of isolates were susceptible to imipenem-cilastatin alone. Relebactam promises to increase the efficacy of imipenem-cilastatin against .
摘要
是一种普遍且危及生命的革兰氏阴性病原体。-衍生的头孢菌素酶（PDC）是 中主要的诱导型头孢菌素酶。在本研究中，我们表明，雷利巴坦是一种二氮杂双环辛烷β-内酰胺酶抑制剂，可有效失活 PDC-3，其 / 值为 41400M s， 值为 0.00095s。雷利巴坦使 62%的多药耐药 临床分离株对亚胺培南的敏感性恢复，而单独使用亚胺培南-西司他丁的分离株仅有 21%敏感。雷利巴坦有望提高亚胺培南-西司他丁对 的疗效。
相似文献
1
Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam.
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02406-17. Print 2018 May.
2
Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program.
Antimicrob Agents Chemother. 2018 Jun 26;62(7). doi: 10.1128/AAC.00169-18. Print 2018 Jul.
3
Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.
J Antimicrob Chemother. 2019 Aug 1;74(8):2284-2288. doi: 10.1093/jac/dkz191.
4
In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.
Int J Antimicrob Agents. 2020 Jan;55(1):105841. doi: 10.1016/j.ijantimicag.2019.10.022. Epub 2019 Nov 6.
5
Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.
Diagn Microbiol Infect Dis. 2019 Oct;95(2):212-215. doi: 10.1016/j.diagmicrobio.2019.05.001. Epub 2019 May 8.
6
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9.
7
In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.
J Antimicrob Chemother. 2018 Jul 1;73(7):1872-1879. doi: 10.1093/jac/dky107.
8
Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City.
Antimicrob Agents Chemother. 2015 Aug;59(8):5029-31. doi: 10.1128/AAC.00830-15. Epub 2015 May 26.
9
Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.
Diagn Microbiol Infect Dis. 2017 Jun;88(2):171-176. doi: 10.1016/j.diagmicrobio.2017.02.018. Epub 2017 Mar 2.
10
Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00174-18. Print 2018 Jun.
引用本文的文献
1
-producing ST654 comprises a quarter of all carbapenem-resistant in blood isolates from 15 hospitals.
Antimicrob Agents Chemother. 2024 Dec 5;68(12):e0096524. doi: 10.1128/aac.00965-24. Epub 2024 Oct 31.
2
Crystal structure of the class A extended-spectrum β-lactamase CTX-M-96 in complex with relebactam at 1.03 Angstrom resolution.
Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0172123. doi: 10.1128/aac.01721-23. Epub 2024 Jul 11.
3
New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Liver Transplantation: Clinical Perspectives, Toxicity, and PK/PD Properties.
Transpl Int. 2024 Feb 1;37:11692. doi: 10.3389/ti.2024.11692. eCollection 2024.
4
Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review.
Microorganisms. 2023 Jul 13;11(7):1798. doi: 10.3390/microorganisms11071798.
5
Susceptibility profile and β-lactamase content of global isolates resistant to ceftolozane/tazobactam and/or imipenem/relebactam-SMART 2016-21.
JAC Antimicrob Resist. 2023 Jun 28;5(3):dlad080. doi: 10.1093/jacamr/dlad080. eCollection 2023 Jun.
6
Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review.
Drugs. 2023 Jul;83(11):967-983. doi: 10.1007/s40265-023-01893-6. Epub 2023 Jun 14.
7
New antibiotics for Gram-negative pneumonia.
Eur Respir Rev. 2022 Dec 21;31(166). doi: 10.1183/16000617.0119-2022. Print 2022 Dec 31.
8
Antibiogram at a Rural Hospital Against the Background of COVID-19: A Five-Year Retrospective Review.
Cureus. 2022 Jul 25;14(7):e27221. doi: 10.7759/cureus.27221. eCollection 2022 Jul.
9
Molecular Mechanism of the β-Lactamase Mediated β-Lactam Antibiotic Resistance of Isolated From a Chinese Teaching Hospital.
Front Microbiol. 2022 Apr 28;13:855961. doi: 10.3389/fmicb.2022.855961. eCollection 2022.
10
Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0133221. doi: 10.1128/AAC.01332-21. Epub 2021 Aug 9.
本文引用的文献
1
Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.
mBio. 2017 Oct 31;8(5):e00528-17. doi: 10.1128/mBio.00528-17.
2
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
J Antimicrob Chemother. 2017 Sep 1;72(9):2616-2626. doi: 10.1093/jac/dkx139.
3
Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6234-43. doi: 10.1128/AAC.00633-16. Print 2016 Oct.
4
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.
Clin Infect Dis. 2016 Jul 15;63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20.
5
Exposing a β-Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase.
Antimicrob Agents Chemother. 2015 Nov 23;60(2):777-88. doi: 10.1128/AAC.02073-15. Print 2016 Feb.
6
Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
Antimicrob Agents Chemother. 2015 Oct;59(10):6248-55. doi: 10.1128/AAC.00825-15. Epub 2015 Jul 27.
7
Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.
J Antimicrob Chemother. 2015 Aug;70(8):2279-86. doi: 10.1093/jac/dkv094. Epub 2015 May 8.
8
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.
Antimicrob Agents Chemother. 2015;59(6):3656-9. doi: 10.1128/AAC.05024-14. Epub 2015 Apr 6.
9
Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
Antimicrob Agents Chemother. 2015 Jul;59(7):3710-7. doi: 10.1128/AAC.04406-14. Epub 2015 Feb 9.
10
Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2015 Feb;59(2):1020-9. doi: 10.1128/AAC.04238-14. Epub 2014 Dec 1.
Zotero 插件